| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H29NO3.ClH |
| Molecular Weight | 367.91 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCC[C@H](C1)OC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3
InChI
InChIKey=LBKCCRHBZAWYOP-HUVSLODASA-N
InChI=1S/C20H29NO3.ClH/c1-21-14-8-13-18(15-21)24-19(22)20(23,16-9-4-2-5-10-16)17-11-6-3-7-12-17;/h2,4-5,9-10,17-18,23H,3,6-8,11-15H2,1H3;1H/t18-,20?;/m1./s1
Propenzolate is a pyridine derivative patented by National Research Development Corp. as an anticholinergic agent. Propenzolate is effective antidotes to the cholinesterase-inhibiting action of various organophosphorus compounds. In clinical trials, Propenzolate has an activity that decreases to some extent the secretion of hydrochloric acid and the volume of gastric juice. Adverse effects, including nausea, vomiting, weakness, and drowsiness, as well as xerostomia and cycloplegia, are observed in a high percentage of patients receiving 0.5 to 1.0 mg. every 12 hours.
Originator
Approval Year
PubMed
Patents
SUBSTANCE RECORD
